A Double Blind, 3rd Party Open, Placebo Controlled, Dose Escalating, Parallel Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04634817 In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2011
At a glance
- Drugs PF 4634817 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 29 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 29 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.